Memorial Day Offer

Discover your mystery discount!


Effects on Lean Mass: – Ibutamoren activates the GH-IGF-1 axis, leading to a significant increase in GH secretion. – It promotes the growth of lean […]

« Back to Glossary Index

Effects on Lean Mass:
– Ibutamoren activates the GH-IGF-1 axis, leading to a significant increase in GH secretion.
– It promotes the growth of lean body mass, muscle mass, and bone mineral density.
– Being explored for potential treatment of frailty in the elderly and growth hormone deficiency.

Effects on Sleep Architecture:
– MK-677 at 25mg/day increased REM sleep by 20% in young subjects and by 50% in older subjects.
– Young subjects experienced a 50% increase in deep sleep with MK-677 treatment.

Growth Hormone Deficiency:
– MK-677 shows promise in improving GH levels in children, outperforming other GH secretagogues.
– Ongoing studies are comparing MK-677 directly to injectable hGH for height velocity.

Non-Research Use and Legal Status:
– MK-677 is still an Investigational New Drug and not approved for human consumption in the US.
– Despite restrictions, some in the bodybuilding community experiment with MK-677.
– Its use is banned in most sports.

References and Additional Information:
– Studies demonstrate MK-677’s impact on GH secretion, IGF-1 levels, sleep quality, and bone turnover.
– Research suggests MK-677 as a potential therapy for frailty in seniors.
– Various sources like AdisInsight,, Molecular Psychiatry, and provide comprehensive data and insights.

Ibutamoren (Wikipedia)

Ibutamoren (INNTooltip International Nonproprietary Name) (developmental code names MK-677, MK-0677, LUM-201, L-163,191; former tentative brand name Oratrope) is a potent, long-acting, orally-active, selective, and non-peptide agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been shown to increase the secretion of several hormones including GH and insulin-like growth factor 1 (IGF-1) and produces sustained increases in the plasma levels of these hormones without affecting cortisol levels.

Clinical data
Other namesMK-677; MK-0677; L-163,191; Oratrope
Routes of
By mouth
Legal status
Legal status
Pharmacokinetic data
Elimination half-life4–6 hours (in beagles); IGF-1 levels remain elevated in humans with a single oral dose for up to 24 hours
  • 2-amino-2-methyl-N-[1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.236.734 Edit this at Wikidata
Chemical and physical data
Molar mass528.67 g·mol−1
3D model (JSmol)
  • O=S(C)(=O)N(C2)c1ccccc1C23CCN(CC3)C(=O)C(NC(=O)C(N)(C)C)COCc4ccccc4
  • InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1
« Back to Glossary Index
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.